Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval
PurposeLittle is known about the use of first-line chemotherapy in clinical practice in patients with advanced esophagogastric adenocarcinoma, and no data have been published regarding potential obstacles for the implementation of molecular testing for targeted agents in this patient group. Here, we...
Saved in:
| Main Authors: | , |
|---|---|
| Other Authors: | , , , , , , , , |
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Journal of cancer research and clinical oncology
Year: 2012, Volume: 139, Issue: 2, Pages: 337-345 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-012-1335-7 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s00432-012-1335-7 Verlag, Volltext: https://link.springer.com/article/10.1007/s00432-012-1335-7 
|
| Author Notes: | Deniz Gencer, Salah-Eddin Al-Batran, Reyad Dada, Ali-Nuri Hünerlitürkoglu, Michael Gonnermann, Thomas Kegel, Harald Scheiber, Wolf-Oliver Jordan, Iris Burkholder, Lenka Kellermann, Ralf-Dieter Hofheinz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572513632 | ||
| 003 | DE-627 | ||
| 005 | 20251215214629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180502r20132012xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-012-1335-7 |2 doi | |
| 035 | |a (DE-627)1572513632 | ||
| 035 | |a (DE-576)502513632 | ||
| 035 | |a (DE-599)BSZ502513632 | ||
| 035 | |a (OCoLC)1341008042 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gencer, Deniz |d 1980- |e VerfasserIn |0 (DE-588)140107940 |0 (DE-627)616027850 |0 (DE-576)314627332 |4 aut | |
| 245 | 1 | 0 | |a Metastatic esophagogastric adenocarcinoma |b trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |c Deniz Gencer, Salah-Eddin Al-Batran, Reyad Dada, Ali-Nuri Hünerlitürkoglu, Michael Gonnermann, Thomas Kegel, Harald Scheiber, Wolf-Oliver Jordan, Iris Burkholder, Lenka Kellermann, Ralf-Dieter Hofheinz |
| 264 | 1 | |c 2013 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 19 October 2012 | ||
| 500 | |a Gesehen am 02.05.2018 | ||
| 520 | |a PurposeLittle is known about the use of first-line chemotherapy in clinical practice in patients with advanced esophagogastric adenocarcinoma, and no data have been published regarding potential obstacles for the implementation of molecular testing for targeted agents in this patient group. Here, we sought to evaluate factors influencing treatment decisions with special focus on the implementation of HER2 testing during the first year after trastuzumab market approval in Germany.MethodsA total of 754 patients undergoing treatment decisions for palliative first-line therapy in 2010 were documented using Therapiemonitor®. Drug use and intensity of first-line treatment were analyzed. Data on HER2 testing and test algorithm are described, and variables influencing HER2 testing were selected using bivariate analysis. Significant factors were included in a multivariate logistic regression analysis.ResultsCompared with previous years, treatment intensity has further increased. The use of chemotherapy triplets rose from 10.1 % in 2006 to 60.3 % in 2010. In 2010, 49.1 % of patients were tested for HER2 and in 52.2 % of these patients the currently proposed test algorithm was used. Using multivariate logistic regression analysis age ≥67 years and “initiating institution: practice” were found to negatively impact the likelihood of HER2 testing, while treatment goal “prevention of progression”, multiple metastases and a Karnofsky status >80 % showed positive correlation with HER2 testing.ConclusionThe tendency to use more intensive first-line chemotherapy regimens in patients with advanced esophagogastric adenocarcinoma continued in 2010. Only a minority of patients had an access to the appropriate molecular diagnostics and therefore to treatment with trastuzumab. The access was limited due to the preselection following individual, clinical and institutional factors. | ||
| 534 | |c 2012 | ||
| 700 | 1 | |a Al-Batran, Salah-Eddin |4 oth | |
| 700 | 1 | |a Dada, Reyad |4 oth | |
| 700 | 1 | |a Hun͏̈erlitur͏̈koglu, Ali-Nuri |4 oth | |
| 700 | 1 | |a Gonnermann, Michael |4 oth | |
| 700 | 1 | |a Kegel, Thomas |4 oth | |
| 700 | 1 | |a Scheiber, Harald |4 oth | |
| 700 | 1 | |a Jordan, Wolf-Oliver |4 oth | |
| 700 | 1 | |a Burkholder, Iris |0 (DE-588)1176548557 |0 (DE-627)104754671X |0 (DE-576)516671278 |4 oth | |
| 700 | 1 | |a Kellermann, Lenka |4 oth | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d Berlin : Springer, 1979 |g 139(2013), 2, Seite 337-345 |h Online-Ressource |w (DE-627)253769515 |w (DE-600)1459285-X |w (DE-576)072578319 |x 1432-1335 |7 nnas |a Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |
| 773 | 1 | 8 | |g volume:139 |g year:2013 |g number:2 |g pages:337-345 |g extent:9 |a Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-012-1335-7 |x Verlag |x Resolving-System |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00432-012-1335-7 |x Verlag |3 Volltext |7 1 |
| 889 | |w (DE-627)783671628 | ||
| 935 | |h GBV |i ExPruef | ||
| 951 | |a AR | ||
| 992 | |a 20180502 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 11 |y j | ||
| 998 | |g 140107940 |a Gencer, Deniz |m 140107940:Gencer, Deniz |d 60000 |d 61200 |e 60000PG140107940 |e 61200PG140107940 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1572513632 |e 3007738261 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"part":{"volume":"139","text":"139(2013), 2, Seite 337-345","year":"2013","issue":"2","extent":"9","pages":"337-345"},"language":["eng","ger"],"title":[{"subtitle":"official organ of the Deutsche Krebsgesellschaft","title":"Journal of cancer research and clinical oncology","title_sort":"Journal of cancer research and clinical oncology"}],"pubHistory":["Volume 93, issue 1 (January 1979)-"],"note":["Gesehen am 19.03.25","Teils ungezählte Beil.: Supplement"],"disp":"Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approvalJournal of cancer research and clinical oncology","id":{"eki":["253769515"],"issn":["1432-1335"],"zdb":["1459285-X"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1979","dateIssuedDisp":"1979-","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg"}],"recId":"253769515","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Cancer research and clinical oncology"}]}],"note":["Published: 19 October 2012","Gesehen am 02.05.2018"],"physDesc":[{"extent":"9 S."}],"id":{"eki":["1572513632"],"doi":["10.1007/s00432-012-1335-7"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2013","dateIssuedKey":"2013"}],"recId":"1572513632","person":[{"display":"Gencer, Deniz","role":"aut","given":"Deniz","family":"Gencer"},{"role":"oth","given":"Salah-Eddin","display":"Al-Batran, Salah-Eddin","family":"Al-Batran"},{"family":"Dada","given":"Reyad","role":"oth","display":"Dada, Reyad"},{"role":"oth","given":"Ali-Nuri","display":"Hun͏̈erlitur͏̈koglu, Ali-Nuri","family":"Hun͏̈erlitur͏̈koglu"},{"family":"Gonnermann","role":"oth","given":"Michael","display":"Gonnermann, Michael"},{"role":"oth","given":"Thomas","display":"Kegel, Thomas","family":"Kegel"},{"display":"Scheiber, Harald","role":"oth","given":"Harald","family":"Scheiber"},{"given":"Wolf-Oliver","role":"oth","display":"Jordan, Wolf-Oliver","family":"Jordan"},{"family":"Burkholder","display":"Burkholder, Iris","given":"Iris","role":"oth"},{"family":"Kellermann","display":"Kellermann, Lenka","role":"oth","given":"Lenka"},{"display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut","family":"Hofheinz"}],"name":{"displayForm":["Deniz Gencer, Salah-Eddin Al-Batran, Reyad Dada, Ali-Nuri Hünerlitürkoglu, Michael Gonnermann, Thomas Kegel, Harald Scheiber, Wolf-Oliver Jordan, Iris Burkholder, Lenka Kellermann, Ralf-Dieter Hofheinz"]},"language":["eng"],"title":[{"title_sort":"Metastatic esophagogastric adenocarcinoma","title":"Metastatic esophagogastric adenocarcinoma","subtitle":"trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval"}]} | ||
| SRT | |a GENCERDENIMETASTATIC2013 | ||